Pharmaceutical CEOs too cowardly to appear before Senate Finance Committee; lackeys instead try to blame the 340B drug discount program, which is only a tiny sliver of the $457 billion U.S. drug market. WASHINGTON (January 29, 2019) US Senate Finance Committee Chairman Chuck Grassley (R-IA) convened an historic hearing on drug prices earlier today and he and the committee ranking … Read More